Smart Immune, Memorial Sloan Kettering expedite development of next-gen CAR T

By The Science Advisory Board staff writers

December 13, 2021 -- Smart Immune is collaborating with Memorial Sloan Kettering Cancer Center (MSK) with the goal of expanding its ProTcell pipeline to address the exhaustion of T-cell therapy and fulfill unmet medical needs in the treatment of liquid and solid cancers.

Smart Immune's T-cell progenitors (ProTcell) improves on conventional approaches to CAR T-cell therapies, which rely on mature T cells to generate a naïve, long-lasting, exhaustion-free CAR T cell population. MSK will contribute to the development of the CAR-ProTcell platform in a mouse-to-mouse model, and Smart Immune will lead the human model.

ProTcell progenitors can be efficiently transduced with a lentiviral vector, according to the groups. The collaboration will further optimize transduction and culturing conditions to perform in vitro and in vivo preclinical studies on ProTcell transduced with a CD19 CAR lentiviral vector.

No financial agreements were disclosed.

Lentiviral cell therapies hold promise for monogenic blood disorders
Lentiviral vectors show promise for monogenic blood disorders and the future is bright for these genetically modified cell therapies, according to Dr. Michel...
Caribou inks deal with MSK to make allogeneic therapies
Memorial Sloan Kettering Cancer Center (MSK) has agreed to exclusively license its antibody fragments to CRISPR genome editing firm Caribou Biosciences...
CAR-T cell therapy research shows encouraging signs for mesothelioma patients
Every year, nearly 3,000 new cases of mesothelioma are diagnosed in the United States. While this is just a small percentage of overall cancer diagnoses,...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter